Table 2.
Clinicopathologic features of bladder tumors in men who received α1-blocker therapy
| Silodosin | Tamsulosin | Naftopidil | P value | ||||
|---|---|---|---|---|---|---|---|
|
| |||||||
| Sil vs. Tam | Sil vs. Naf | Sil vs. Tam+Naf | Tam vs. Naf | ||||
| Bladder tumors | 49/540 (9.1%) | 64/523 (12.2%) | 28/236 (11.9%) | 0.094 | 0.232 | 0.082 | 0.884 |
| Age (mean ± SD, yr) | 74.3 ± 7.9 | 75.6 ± 9.9 | 71.8 ± 8.0 | 0.426 | 0.196 | 0.904 | 0.055 |
| Tumor grade | 0.418 | 0.188 | 0.257 | 0.488 | |||
| Low grade | 32 (65.3%) | 37 (57.8%) | 14 (50.0%) | ||||
| High grade | 17 (34.7%) | 27 (42.2%) | 14 (50.0%) | ||||
| Tumor stage | 0.330 | 0.397 | 0.300 | 0.977 | |||
| NMI (≤pT1) | 45 (91.8%) | 55 (85.9%) | 24 (85.7%) | ||||
| MI (≥pT2) | 4 (8.2%) | 9 (14.1%) | 4 (14.3%) | ||||
| Recurrence of NMI | 16 (35.6%) | 27 (49.1%) | 12 (50.0%) | 0.174 | 0.245 | 0.137 | 0.941 |
| Progression of NMI | 1 (2.2%) | 6 (10.9%) | 5 (20.8%) | 0.090 | 0.009 | 0.034 | 0.241 |
| Progression of MI | 0 (0%) | 7 (77.8%) | 2 (50.0%) | 0.009 | 0.103 | 0.015 | 0.317 |
Sil: silodosin; Tam: tamsulosin; Naf: naftopidil; NMI: non-muscle-invasive; MI: muscle-invasive.